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Abstract
Background/Aim: Targeted radiotherapy of liver malignancies has found to be effective in selected patients. A key limiting
factor of these therapies is the relatively low tolerance of the liver parenchyma to radiation. We sought to assess the
preventive effects of a combined regimen of pentoxifylline (PTX), ursodeoxycholic acid (UDCA) and low-dose low molecular
weight heparin (LMWH) on focal radiation-induced liver injury (fRILI).
Methods and Materials: Patients with liver metastases from colorectal carcinoma who were scheduled for local ablation by
radiotherapy (image-guided high-dose-rate interstitial brachytherapy) were prospectively randomized to receive PTX, UDCA
and LMWH for 8 weeks (treatment) or no medication (control). Focal RILI at follow-up was assessed using functional
hepatobiliary magnetic resonance imaging (MRI). A minimal threshold dose, i.e. the dose to which the outer rim of the fRILI
was formerly exposed to, was quantified by merging MRI and dosimetry data.
Results: Results from an intended interim-analysis made a premature termination necessary. Twenty-two patients were
included in the per-protocol analysis. Minimal mean hepatic threshold dose 6 weeks after radiotherapy (primary endpoint)
was significantly higher in the study treatment-group compared with the control (19.1 Gy versus 14.6 Gy, p = 0.011).
Qualitative evidence of fRILI by MRI at 6 weeks was observed in 45.5% of patients in the treatment versus 90.9% of the
control group. No significant differences between the groups were observed at the 12-week follow-up.
Conclusions: The post-therapeutic application of PTX, UDCA and low-dose LMWH significantly reduced the extent and
incidence fRILI at 6 weeks after radiotherapy. The development of subsequent fRILI at 12 weeks (4 weeks after cessation of
PTX, UDCA and LMWH during weeks 1–8) in the treatment group was comparable to the control group thus supporting the
observation that the agents mitigated fRILI.
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Introduction
Highly targeted radiotherapy of liver malignancies has found to
be effective in selected patients. Stereotactic radiotherapy, radio-
embolization using yttrium-90 (90Y) microspheres as well as image-
guided brachytherapy (BT) have been described in the literature
with promising results [1,2,3]. A key limiting factor of these
therapies is the relatively low tolerance of the liver parenchyma to
radiation leading to either subclinical focal or generalized injury of
the liver parenchyma. When the intensity or the extent of
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radiation-induced liver injury (RILI) exceeds the functional
reserve, clinical complications appear in the form of radiation
(radioembolization) induced liver disease (RILD or REILD)
[4,5,6,7]. Prior exposure or concomitant chemotherapy is thought
to increase the risk of RILD (or REILD), and as a consequence is a
relatively common complication, for example, after conditioning
therapy prior to bone marrow transplantation (BMT) [5,8,9,10].
Liver damage whether associated with whole body irradiation or
liver-directed radiotherapy have the same pathology, i.e. veno-
occlusive disease (VOD) [5,11,12,13].
Medication designed to reduce RILI could improve the safety as
well as enable more aggressive radiotherapy. Clinical studies have
shown with varying strength of evidence that VOD/RILD after
BMT can be ameliorated by pentoxifylline (PTX), ursodeoxy-
cholic acid (UDCA) and low molecular weight heparin (LMWH)
[14,15,16,17,18,19,20,21,22] (see Table 1). However, the equiv-
ocal nature of the results from most studies probably reflect the
heterogeneous study populations (including patients who have
received prior chemotherapy or had underlying liver disease) [23].
Thus, a more standardized clinical model is needed to evaluate the
protective effects of prophylactic regimens against VOD/RILD.
Image-guided, single-fractioned, high-dose-rate BT of liver
malignancies is associated with a well-characterized focal RILI
(fRILI), which can be visualized and quantified using functional
hepatobiliary magnetic resonance imaging (MRI) (see Figure 1)
[6,7]. Importantly, the histopathological evidence of fRILI (i.e.
sinusoidal congestion with hepatocyte atrophy and increased
reticulin deposits) correlates well with the absence of the
hepatocyte uptake of hepatolbiliary MRI contrast media [24].
We have previously found that development of areas of fRILI were
maximal at 6–8 weeks post-BT which correlates to the peak
incidence of RILD/REILD after conditioning therapy/radio-
embolization througout the first 2 months post-intervention
[5,6,7,25]. We conducted a prospective study to quantify fRILI
in patients who were randomized to BT with and without
prophylactic PTX, UDCA and low-dose LMWH. To minimize
the confounding effects of prior chemotherapy on radiation
tolerability, only patients with liver metastases from colorectal
cancer (mCRC) were included because these patients tend to have
a more consistent pattern of prior exposition to chemotherapy.
The cumulative effect of three drugs over a period of 8 weeks
[26,27,28] was assessed and patients followed-up at 6 and 12
weeks.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
This was a prospective, randomised phase II, parallel-group,
open-label study conducted at a single centre. The study was
approved by the competent authorities (Federal Institute for Drugs
and Medical Devices (in german: Bundesinstitut fu¨r Arzneimittel
und Medizinprodukte - BfArM)) and the local ethics committee
(Ethikkommission der Otto-von-Guericke-Universita¨t der Medizi-
nischen Fakulta¨t). Trial registration: Eudra-CT: 2008-002985-70;
ClinicalTrials.gov-identifier NCT01149304. Written informed
consent was obtained from all patients prior to study entry.
Group allocation approach was unrestricted randomization.
Patient characteristics
Consecutive patients (18–80 years) with liver metastases from
mCRC, who were scheduled for local ablation with computed-
tomography (CT)/MRI-guided BT between 2009 and 2012, were
screened (Figure 2). (BT is the local standard ablative treatment in
patients ineligible for surgical or all other appropriate interven-
tion).
Women who were pregnant, lactating or of childbearing
potential were excluded as were patients with liver cirrhosis,
hepatitis B or C, severe coronary artery disease, autoimmune
diseases, acute bacterial endocarditis, active major bleedings or
high-risk of uncontrolled hemorrhage; severe or moderate renal
impairment (GFR ,60 mL/min), or known contraindication or
hypersensitivity to any of the study treatments or procedures.
Treatment and follow-up
Patients received a single-fraction, CT- or MRI-guided BT of
CRC liver metastases (see details below). In those randomized to
prophylaxis, the following treatment was initiated during the
evening of the day of BT: sc injection of 40 mg q.d. enoxaparin
(Clexane, Sanofi Aventis, Paris, France) [20], oral 400 mg t.i.d.
PTX (Trental, Sanofi Aventis) [16] and oral 250 mg t.i.d. UDCA
(Ursofalk, Falk Pharma, Freiburg, Germany) [17,19]. Patients
were discharged usually on the third day post-BT and continued to
take study medication at home for 8 weeks. All patients were
followed-up on day 3, week 6 and 12 with an optional follow-up at
week 24. Within 24 hours of the procedure and at each subsequent
visit, blood samples were taken for liver-specific and inflammato-
ry/hemostatic laboratory parameters, and patients were assessed
for ECOG-performance status and health-related quality-of-life
(using the EQ5D-questionnaire). All adverse reactions related to
the study medication or BT were recorded.
Compliance to the prophylactic regimen was evaluated during a
dialogue at each visit and the evaluation of anti-Xa-activity at 6
weeks. Insufficient compliance was determined by: either anti-Xa-
activity,0.1 IU/mL measured up to 4 hours after last enoxaparin
injection, or two dose interruptions of the prophylactic regimen for
more than 1 day/week. Non-compliant patients were withdrawn
from the per-protocol analysis and study-specific medication
stopped.
Image-guided interstitial brachytherapy
The technique of image-guided BT has been described
previously [2]. Briefly, the placement of the introducer sheaths
(6F Radiofocus, Terumo, Tokyo, Japan) with the BT applicators
(Lumencath, Nucletron/Elekta, Veenendaal, The Netherlands)
was performed using CT or MRI fluoroscopy. For treatment
planning purposes, a spiral CT or T1-weighted MRI of the liver
(reconstructed slice thickness: 3 mm) enhanced by intravenous
application of iodine contrast media (CT) or Gd-EOB-DTPA
(MRI) was acquired.
The high-dose-rate afterloading system (Microselectron, Nucle-
tron/Elekta, Veenendaal, The Netherlands) employed an iridium-
192 source with a nominal activity of 10Ci (i.e. 370GBq); decay
correction was performed daily. Relative coordinates (x, y, z) of the
catheters were determined in the CT/MRI-data set and trans-
ferred to the treatment planning system (Oncentra, Nucletron/
Elekta). Using these coordinates, the clinical target volume and the
predefined minimum dose (20 Gy, delivered as a single fraction
[2]), the software calculated a dosimetry and the duration of the
iridium-192 source inside the BT catheters. A planning CT with
dosimetry is displayed in Figure 1B and F.
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Magnetic resonance imaging
MRI (Achieva 1.5T, Philips, Best, The Netherlands) using the
hepatobiliary contrast medium Gd-EOB-DTPA (Primovist, Bayer
Healthcare, Leverkusen, Germany) was performed 1 day before
and 6 and 12 weeks post-BT. MR-sequence of events was as
follows: axial 3D T1-weighted (T1-w) gradient echo THRIVE
(T1-High-Resolution-Isotropic-Volume-Excitation) (Time-to-
Echo/Time-to-Repetition 4/10 ms, flip-angle 10u) with fat-
suppression pre-contrast, at 20 s, 60 s and 120 s and 20 minutes
after iv 0.1 mL/kg bodyweight Gd-EOB-DTPA. The slice
thickness was 3 mm. For the study-specific MRI volumetry,
dynamic THRIVE at 60 s (for the exclusion of tumor progression/
local recurrence) and hepatobiliary phase THRIVE 20 min after
application of Gd-EOB-DTPA (for the determination of area of
fRILI) were mandatory.
Identification of the radiation isodose (minimal hepatic thresh-
old dose) that demarcated the border between the fRILI and
functioning liver tissue (as defined by non-uptake and uptake of
Gd-EOB-DTPA enhanced MRI, respectively) was performed as
follows in a blinded matter.
The hepatobiliary phase THRIVE was transferred to the BT-
planning software. Image registration of the hepatobiliary phase
THRIVE to the contrast-enhanced planning CT/MRI (including
the dosimetry) was performed by an isoscalar local semi-
automated point-based 3D-3D image registration using predefined
match points (3 or 4 corresponding landmarks restricted to liver
structures). Registration was only accepted if the target area
merged perfectly by visual assessment. As a result of this
procedure, the software simultaneously displayed the treatment
dosimetry and anatomical structures/fRILI of the hepatobiliary
phase THRIVE. The volume of the liver parenchyma with
radiation-induced impaired uptake of Gd-EOB-DTPA (i.e. fRILI)
was determined. The isodose of the dosimetry encircling this
volume was determined at five different axial levels and the mean
of these values recorded. This dose resembles the dose which was
formerly applied at the now demarcated rim of the fRILI,
corresponding to the assumed minimal hepatic tolerance dose. To
ensure a negligible registration error, the volume of fRILI was
inserted into the dose-volume-histogram of the dosimetry. The
corresponding isodose was stored. Results of the two methods
showed a high correlation of 0.899 and 0.562 (p,0.001 and
p= 0.006) for 6 and 12 weeks, respectively. To minimize
methodological errors, the mean isodose value of the two methods
was taken. In case of more than one treated lesion, the mean of the
determined isodoses was used. If no detectable fRILI was seen in
follow-up, the minimal mean hepatic threshold dose was defined
as the dose which was previously administered at the tumor
margin (since an effect on the liver parenchyma above this dose
level cannot be excluded). Figure 1 illustrates the development and
appearance of the fRILI in hepatobiliary phase THRIVE.
Endpoints and statistical analyses
The aim of the study was to assess if a combination regimen of
PTX, UDCA and low-dose LMWH for 8 weeks provided a
preventive effect regarding irradiation damage to liver parenchy-
ma (as resembled by the minimal mean threshold dose of the
fRILI volume) at 6 weeks (primary endpoint) and at 12 weeks
(secondary endpoint) after BT.
As additional descriptor, detectable fRILI in Gd-EOB-DTPA
MRI (yes/no) was recorded at each follow-up. Further secondary
objectives included the safety of the study treatment after BT
including changes in bilirubin and albumin which were graded
according to Common Terminology Criteria for Adverse Events
version 3 (CTCAE3.0).
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The relation between hepatocyte dysfunction and changes in
the following liver-specific and inflammatory/hemostatic labora-
tory values were analysed: fibrinogen, factor-VIII-activity, inter-
leukin-6, protein-C-activity, protein-S-activity, von-Willebrand-
factor-activity and antithrombin-III-activity [29].
Determination of sample size was based on the expected
minimum between-group difference of 2.1 Gy (SD 2.3 Gy) for
minimal mean hepatic threshold dose at 6 weeks after BT (from
9.9 Gy to 12 Gy) [7]. A sequential test with 2 stages according to
the Pocock-design was used which yielded a total of 22
observations per group with a scheduled interim analysis after
11 observations per group when a= 0.025 and power 1-b= 0.8.
Interim-analysis showed a significant difference between the
groups regarding the primary variable with a one-sided p-value
of 0.011. A one-sided p of ,0.0148 was necessary to terminate the
study prematurely.
Statistical analysis was performed using SPSS (SPSS21, IBM,
Chicago, Il, USA). Descriptive analysis of patient characteristics
and laboratory findings was performed. The primary analysis was
evaluated in the per protocol cohort and repeated in the intention-
to-treat population as sensitivity analysis. Between-group differ-
ences in minimal mean hepatic threshold after BT at 6 and 12
weeks were compared using a two-sample t-tests, and evidence of
detectable fRILI were compared using the Fisher’s-exact-test.
Possible confounding factors were evaluated using the Mann-
Whitney-U-test for metric variables and the Fisher’s-exact-test for
categorical variables, and then between-group differences for the
primary endpoint were evaluated with inclusion of the covariables
(ANOVA and ANCOVA). The relationship between the minimal
mean hepatic threshold dose and laboratory values was tested by
Pearson’s correlation and ANCOVA. Group comparison regard-
ing ECOG and EQ5D was made by Mann-Whitney-U-test.
Median overall survival was estimated by Kaplan-Meier (group
comparison by log-rank test). A p-value of ,0.05 was statistically
significant.
Results
Of 129 patients screened with liver metastases from colorectal
cancer scheduled for BT, 30 patients were included in the study
and 22 patients (11 per group) in the primary analyses of the per-
protocol group (see CONSORT diagram, Figure 2). Demograph-
ic characteristics of randomized patients at screening are
summarized in Table 2 and the baseline liver function and other
laboratory parameters are presented in Table 3. Group compar-
ison revealed a similar distribution of possible confounders. A
tendency towards a larger volume of significantly radiation
exposed liver parenchyma (.10 Gy) in the study treatment group
(Table 2) may have potentially lowered the hepatic tolerance dose
in this group instead of increase it [25].
The minimal mean hepatic threshold dose at 6 weeks after BT
(primary endpoint) was significantly higher in the study treatment
group than the control (19.1 Gy versus 14.6 Gy, p = 0.011,
Table 4) with comparable results with the intention-to-treat
analysis (Table 4). Correspondingly, fewer patients in the study
treatment group than the control had evidence of fRILI at 6 weeks
(45.5% versus 90.9%); this difference was also significant in the
intention-to-treat analysis (Table 4). However at 12 weeks after
BT (and 4 weeks after cessation of study treatment), these between-
group differences were not observed (in neither the per-protocol
nor intention-to-treat analyses) for the minimal mean hepatic
threshold dose and the proportion of patients with fRILI (Table 4).
Results from the optional follow-up at 24 weeks after BT
continually showed no between-group differences for the minimal
Figure 1. T1w-axial THRIVE 20 min after application of Gd-EOB-DTPA (A, C–E and G, H) and BT planning CT with dosimetry (B and
F). A–D, control group. A: pre-treatment MRI displaying a metastasis scheduled for BT treatment (black arrow). B: Planning-CT after introduction of
the brachytherapy catheters (black arrows). Clinical target volume (CTV) represented by bold red circle and dosimetry by coloured lines (red: 20 Gy-,
blue: 12 Gy-isodose). C: MRI at 6 weeks showing substantial reduction in Gd-EOB-DTPA uptake by liver parenchyma adjacent to treated metastases
(i.e. focal radiation-induced liver injury, fRILI). Note: The area of fRILI matches the geometry of the dosimetry (B). Determined threshold dose: 9.75 Gy.
D: MRI at 3 months showing shrinkage of the fRILI. Determined threshold dose: 11.9 Gy. E–H, treatment group. E: pre-treatment MRI displaying two
metastases (black arrow); two more treated lesions are not displayed in the plane. F: Planning-CT (annotations: see B). G: MRI at 6 weeks showing no
fRILI. H: MRI at 3 months after radiotherapy (and 1 month after finishing study treatment) showing a substantial region of fRILI. Determined threshold
dose: 15.8 Gy.
doi:10.1371/journal.pone.0112731.g001
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mean hepatic threshold dose and the proportion of patients with
fRILI (no change of the proportion of patients with fRILI as
compared to 12 weeks follow-up; the minimal mean hepatic
threshold dose for treatment group was 20.1 Gy (1 patient missing)
and for the control group 21.0 Gy; p.0.05, per-protocol analysis
(with comparable results with the intention-to-treat analysis)).
Covariate analyses also showed no influence of recorded
covariables on the primary endpoint; only group allocation was
significant (Table 5).
EQ5D (as a descriptor of quality of life) and distribution of
ECOG performance status were not significantly different at
baseline (Table 2) or at any follow-up visit (Table S1). Median
overall survival from time of BT on was not different between the
groups with 30.0 months (95%CI: 8.7–51.3) in the treatment
group and 39.5 months (27.5–51.5) in the control group
(p = 0.430).
Safety analyses were conducted in all 30 patients who received
BT. The following mild-to-moderate adverse events CTCAEv3
grade 1–2 were reported (in the treatment/control groups) on day
Figure 2. CONSORT-diagram. *Exclusion criterion age was initially disregarded by error in this patient (aged 82). **Exclusion criterion prior
radiotherapy was initially disregarded by error in this patient (prior radiotherapy was performed 2 years earlier with location in the contralateral liver
lobe).
doi:10.1371/journal.pone.0112731.g002
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3 after BT: pain (1 patient/1 patient) and fatigue (0/1); at week 6:
pain (2/0), fatigue (0/1), nausea (1/0) and diarrhea (2/0); nausea
and diarrhea was probably related to PTX or UDCA. One grade
3 subacute bleeding episode from the bile duct, related to BT,
occurred in the study treatment group which was successfully
managed by endoscopic coagulation.
Analysis of the laboratory data revealed no grade 3/4 changes
in bilirubin or albumin. One grade 1 reduction of albumin in the
treatment group at 6 weeks was unchanged at week 12. One
patient in control group with elevated (grade 1) bilirubin at
baseline remained stable throughout follow-up. RILD was not
observed on either group.
Laboratory analysis regarding liver-specific and inflammatory/
hemostatic parameters found no relevant findings at baseline
(Table 3). At week 6, slightly higher gamma-glutamyl-transferase
levels and protein-S-activity were recorded in the control group
compared with the treatment group. At 6 and 12 weeks, there was
slight but significant mean decrease from baseline in cholinesterase
in the treatment group. Additionally, mean fibrinogen and von-
Willebrand-factor-activity increased significantly from baseline in
the treatment group at 6 and 12 weeks; while significant increases
from baseline were recorded with mean fibrinogen, factor-VIII-
activity and aspartate-transaminase in the control group at 6
weeks.
No correlation between the minimal mean hepatic threshold
and liver-specific and inflammatory/hemostatic laboratory values
was found at either week 6 or 12 (data not shown).
Discussion
In this prospective study, we were able to show a significant
reduction in fRILI (as measured by hepatobiliary MRI) at 6 weeks
after BT of colorectal liver metastases in patients who received
low-dose LMWH, PTX and UDCA. Re-assessment of patients at
12 weeks (4 weeks after cessation of study treatment) found that the
extent and incidence of fRILI was comparable to the control
group, thereby supporting the reliability of our findings. This is
further authenticated by the results of the (optional) 24 weeks
follow-up. According to our results we believe that we were able to
mitigate rather than delay the fRILI by the prophylactic regimen.
The finding that the positive effect of the medication to the liver
parenchyma as seen at the 6 weeks follow-up vanished after
discontinuation of the medication (after 8 weeks) in the 3 months
Table 2. Patient characteristics (per protocol analysis).
Variable
Treatment
group (n =11)
Control
(n= 11)
p-value
(between
group)*
Sex (m/f) 9/2 8/3 1.000
Age (years) 71.0965.47 65.09612.55 0.408
Weight (kg) 84.64611.68 83.91612.89 0.592
Height (cm) 174.0966.79 172.6466.90 0.834
ECOG at baseline (0/1/2) 6/4/1 4/5/2 0.370
EQ5D visual analogue score 72.36614.56 76.36613.02 0.446
History of liver surgery 45.5% 45.5% 1.000
Steatosis hepatis 36.4% 18.2% 0.635
Diabetes mellitus 18.2% 27.3% 1,000
Chemotherapy pretreatment
Applied lines 1.0060.63 1.0060.45 1.000
no chemotherapy 18.2% 9.1% NA
1 line 63.6% 81.8% 0.672
2 lines 18.2% 9.1% NA
Prior chemotherapy
Oxaliplatin 63.6% 63.6% 1.000
Irinotecan 36.4% 36.4% 1.000
Biologicals 54.5% 54.5% 1.000
Number of treated metastases 1.9161.04 1.4560.52 0.382
Maximum diameter of metastases (mm) 37.18612.91 29.45611.79 0.146
Clinical target volume (cm3) 42.82629.26 31.36637.14 0.156
Number of used brachytherapy catheters 3.1861.78 2.2761.74 0.079
Liver volume (cm3) 1296.16226.6 1451.36278.6 0.401
Interval between BT and 6 weeks FU (days) 43.9164.76 45.0964.68 0.757
Interval between BT and 3 months FU (days) 87.3464.52 89.5566.15 0.505
Liver volume with a dose exposure .10 Gy (%) 22.55614.45 11.95610.43 0.056
Chemotherapy during follow-up 18.2% 9.1% 1.000
Continuous data: mean 6 standard deviation, frequencies: counts or percent.
*Group comparison, continuous data compared by Mann-Whitney U test, frequency data compared by Pearson’s chi square test.
doi:10.1371/journal.pone.0112731.t002
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Table 3. Laboratory parameters at baseline and follow-up (per protocol analysis).
Variable
(normal range)
Treatment
group (n=11)
Control
(n = 11)
p-value
(between
group)*
p-value
(baseline vs.
follow-up)**
Bilirubin baseline 8.2762.92 8.3965.61 0.594
(,21.0 mmol/L) 6 weeks 9.5869.94 9.5667.18 0.641 0.182 (0.350)
12 weeks 8.7164.27 8.7565.95 0.735 0.594 (0.505)
Albumin baseline 44.2163.46 44.0562.45 0.833
(35.0–52.0 g/L) 6 weeks 42.4965.16 42.6763.17 0.743 0.197 (0.060)
12 weeks 42.8464.94 43.6662.31 0.743 0.212 (0.332)
Cholinesterase baseline 149.26647.97 144.73621.73 0.718
(88–215 mmol/s.L) 6 weeks 136.27651.65 143.82629.10 0.433 0.023 (0.929)
12 weeks 132.94649.22 153.36630.96 0.088 0.010 (0.423)
Aspartate transaminase baseline 0.5660.18 0.4660.17 0.211
(0.17–0.83 mmol/s.L) 6 weeks 0.5960.17 0.5560.23 0.533 0.373 (0.016)
12 weeks 0.6360.47 0.5460.17 0.974 0.563 (0.056)
Alanine transaminase baseline 0.4460.20 0.5160.36 1,000
(0.17–0.83 mmol/s.L) 6 weeks 0.5060.18 0.6260.45 0.742 0.443 (0.109)
12 weeks 0.5360.43 0.5260.27 0.718 0.508 (0.722)
Gamma glutamyltransferase baseline 1.6162.62 1.4961.21 0.189
(0.17–1.19 mmol/s.L) 6 weeks 0.8260.83 2.2161.71 0.011 0.100 (0.050)
12 weeks 1.2561.17 1.9761.49 0.139 0.722 (0.306)
Glutamate dehydrogenase baseline 104.36691.47 108.82694.84 0.844
(,120 nmol/s.L) 6 weeks 67.55631.43 123.276105.88 0.490 0.328 (0.308)
12 weeks 128.116108.79 126.09695.19 0.849 0.674 (0.374)
International normalized baseline 93.963.03 95.5562.98 0.053
ratio (0.85–1.27) 6 weeks 94.1162.71 94.862.44 0.399 0.438 (0.502)
12 weeks 94.6362.50 95.3363.61 0.732 0.334 (0.498
Interleukin 6 baseline 4.5463.31 3.7163.09 0.245
(,7.0 pg/mL) 6 weeks 8.4468.53 7.6264.41 0.809 0.266 (0.038)
12 weeks 10.5069.24 4.0662.42 0.229 0.139 (0.515)
Fibrinogen baseline 3.7260.53 3.9960.46 0.377
(1.50–4.00 g/L) 6 weeks 4.5061.17 4.7760.84 0.365 0.014 (0.017)
12 weeks 4.6561.04 4.2360.49 0.416 0.037 (0.214)
Factor VIII activity baseline 169.09641.51 160.60642.12 0.756
(70–150%) 6 weeks 195.45661.02 218.91660.77 0.490 0.130 (0.093)
12 weeks 199.7667.26 257.096150.23 0.360 0.169 (0.017)
Protein C activity baseline 107.36633.99 109.70612.46 0.145
(.70%) 6 weeks 108632.68 106.55618.67 0.767 0.799 (0.475)
12 weeks 101.5627.26 114619.76 0.084 0.113 (0.540)
Protein S activity baseline 85.36612.26 86.80612.55 0.848
(.60%) 6 weeks 82.18615.16 104.36627.09 0.036 0.266 (0.086)
12 weeks 87.3614.54 91610.6 0.549 0.799 (0.507)
von Willebrand factor baseline 164.09642.81 174.90671.14 0.973
activity (70–130%) 6 weeks 222.27659.75 201.73671.76 0.554 0.013 (0.075)
12 weeks 209.5677.35 215.27675.31 0.883 0.013 (0.333)
Antithrombin III activity baseline 92.73613.72 98.90611.50 0.191
(.80%) 6 weeks 96.73615.31 98.269.78 0.944 0.082 (0.779)
12 weeks 96.4612.08 96.7369.51 0.751 0.407 (0.681)
*Between group comparison, Mann-Whitney U test;
**Comparison versus baseline (in brackets p-value of control group), Wilcoxon test.
doi:10.1371/journal.pone.0112731.t003
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follow-up, make us believe that the fRILI was in fact mitigated in
that period. Further on, the extent of the fRILI at 6 weeks in the
treatment group and at 3 months (and 6 months) in both groups
was less in size compared to the fRILI in the control group at 6
weeks (the peak of the fRILI in our study). Thus, the maximum
extent of the fRILI at 6 weeks was skipped in the treatment group
as compared to the control group. However, the radiation damage
could not be suppressed completely by the prophylactic regimen
with a rebound after cessation of the treatment to the level of the
control group in later follow-ups. Thus, it is possibly right to
assume additionally a delay on the development of the fRILI by
the prophylactic regimen. This delay is considered to be
advantageous as well since a rapid formation of the fRILI can
be delayed (and mitigated) allowing the liver remnant to
compensate for the fRILI. However, although appropriately
powered, the study should be understood as a pilot due to the
small sample size. To compensate for the rebound of the fRILI
after cessation of the prophylactic regimen and for a better
understanding of the dynamics of the fRILI, a study concept with
a prolonged course for the prophylactic regimen is planned.
RILI remains a challenge in the treatment of liver malignancies
by radiotherapy (whether percutaneous, interstitial or by radio-
embolization) because it may eventually translate into RILD or
REILD. Further on, life-threatening VOD associated with
combined-modality induced liver disease occurs in 5–60% of
patients undergoing BMT [18,23,26]. For this reason, the
potentially protective effects of a number of treatments including
low-dose LMWH, PTX and UDCA have been evaluated.
Although the efficacy appears equivocal in some studies
[14,15,16,17,18,19,20,21,28] (Table 1), we determined that the
combination of low-dose LMWH, PTX and UDCA appeared to
be the most promising option for further evaluation with BT. We
believe that our success in showing a benefit in ameliorating fRILI
with this combination is based on the following factors: a highly
homogeneous patient cohort; attention to patient compliance to
the prophylactic regimen; and direct measurement of damage to
the liver parenchyma rather than clinical endpoints.
The treatment course of 8 weeks for the medication was
determined on the assumption that occurrence of RILD and fRILI
peaks around 2 months after radiation-exposure [5,6,7,25].
However, our findings suggest that the radiation-induced injury
to the liver structures and cell endothelial continues beyond 8
weeks and that discontinuation of the medication at this time
allows the development of a veno-occlusive state/liver cell
dysfunction. Endothelial cell damage, which triggers local
thrombotic mechanisms, leading to microvascular flow insuffi-
ciency, production of cytotoxic substances, and ultimately
hepatocellular necrosis, has been thought to be an early event in
the development of RILD/VOD [5,10,11,30,31]. The current
evidence indicates that PTX, low-dose LMWH and UDCA may
act through a variety of mechanisms to alleviate these effects.
PTX, for example, down regulates tumor-necrosis factor-a (TNF-
a), a prime suspect in either the initiation or amplification of tissue
injury following radiation. PTX also stimulates vascular endothe-
lial production of non-inflammatory prostaglandins of the E- and
I-series, enhancing loco-regional blood flow and promoting
thrombolysis [16].
LMWHs are assumed to prevent subsequent thrombosis of
hepatic venules after endothelial damage and therefore decrease
the risk of VOD/RILD [18].
By oral administration of UDCA the concentration of
potentially liver toxic hydrophobic bile acids can be reduced
[32]. Several in vitro studies suggest that potential attenuating
effects of UDCA on the pathogenesis of VOD is achieved through
the down-regulation of inflammatory cytokine such as TNF-a and
interleukin-1 [33]. These cytokines not only induce and amplify
liver damage but are also associated with apoptosis in endothelial
cells [34] and the development of VOD. UDCA also appears to
have a direct effect on programmed-cell death, inhibiting
apoptosis and protecting against the membrane damaging effects
associated with hydrophobic bile acids in both hepatocytes and
non-liver cells [35].
The rationale for this combined treatment approach is based on
the assumption that LMWH, PTX and UDCA, which act through
a variety of different mechanisms, may act synergistically or in a
complimentary fashion to protect the liver [26,27,28]; although
further study is needed to fully evaluate this hypothesis. However,
based on the low toxicity profile of these medications, we believe
Table 4. Minimal mean hepatic tolerance dose (Gy) and evidence of detectable focal radiation-induced liver injury (fRILI) after BT,
group comparison.
Variable Group
p-value
(between groups)
Minimal mean hepatic
tolerance dose
(primary endpoint)
Dose (Gy) SD
At 6 weeks Control 14.64 [14.15] 4.01 [3.93]
Treatment 19.06 [18.46] 3.35 [3.59] 0.011 [0.007]
At 12 weeks Control 16.38 [16.10] 3.57 [3.60]
Treatment 19.04 [18.50] 2.88 [3.11] 0.069 [0.082]
Detectable fRILI Counts Frequency
At 6 weeks Control 10 [12] 90.9% [92.3%]
Treatment 5 [7] 45.5% [53.8%] 0.022 [0.027]
At 12 weeks Control 10 [12] 90.9% [92.3%]
Treatment 10 [12] 90.9% [92.3%] 1.000 [1.000]
Per protocol analysis (n = 22); Intention-to-treat analysis (n = 26) in square brackets.
doi:10.1371/journal.pone.0112731.t004
Reduction of Radiation-Induced Liver Damage
PLOS ONE | www.plosone.org 9 November 2014 | Volume 9 | Issue 11 | e112731
that this initial approach can be justified. Although the patient
numbers are small, the absence of severe toxicities acccords with
experience of other published data [15,16,17,19,20,21,28].
Regarding changes of laboratory values, no clinically relevant
(grade 3/4) toxicities were observed. The observed slight increases
(varying over time and group) of fibrinogen, factor-VIII-activity,
protein-S-activity and von-Willebrand-factor-activity correspond
most likely to an unspecific increase in acute-phase proteins after
radiotherapy or/and to a consequence of radiation-induced
endothelial damage of the hepatic veins and sinuses with
subsequent platelet aggregation. Regarding the course of liver
specific laboratory paramters after BT, it might be argued that the
induced fRILI was possibly too small to induce a significant overall
increase of these parameters. However, the slight but significant
increase of aspartate transaminase in the control group indicates a
parenchymal damage. Interestingly, this increase was not seen in
the treatment group, indicating a decreased parenchymal damage
under preventive medication.
The primary endpoint in our analysis is based on a surrogate i.e.
fRILI visualized and quantified using hepatobiliary contrast agent
(Gd-EOB-DTPA)-enhanced MRI. Hepatobiliary contrast agents
differ from other gadolinium chelates in that they are selectively
taken up by functioning hepatocytes through an organic-anion-
transporter-polypeptide (mainly OATP1B1 and 3) and excreted
Table 5. Covariate analysis of minimal mean hepatic tolerance dose 6 weeks after BT (per protocol, n = 22).
Covariate*
p-value
(group influence)
p-value
(co-variate influence)
Sex (m/f) 0.015 0.458
Age (y) 0.016 0.864
Weight (kg) 0.010 0.117
Height (cm) 0.011 0.485
ECOG at baseline (0 and 1 vs 2) 0.008 0.310
EQ5D visual analogue score 0.015 0.868
History of liver surgery 0.007 0.064
Steatosis hepatis 0.014 0.845
Diabetes mellitus 0.015 0.627
Chemotherapy pre treatment 0.012 0.373
Used chemotherapeutic agents
Oxaliplatin 0.013 0.991
Irinotecan 0.011 0.327
Biologicals 0.012 0.459
Number of treated metastases 0.013 0.681
Maximum diamter of metastases (mm) 0.023 0.669
Clinical target volume (cm3) 0.013 0.815
Liver volume (cm3) 0.018 0.937
Interval from BT to 6 weeks FU (days) 0.008 0.258
Liver volume with a dose exposure .10 Gy (%) 0.013 0.598
Chemotherapy during follow-up 0.015 0.191
Bilirubin baseline 0.030 0.401
Albumin baseline 0.020 0.784
Aspartate transaminase baseline 0.025 0.263
Alanine transaminase baseline 0.006 0.092
Cholinesterase baseline 0.013 0.425
Gamma glutamyltransferase baseline 0.012 0.317
Glutamate dehydrogenase baseline 0.011 0.352
International normalized ratio baseline 0.008 0.783
Interleukin 6 baseline 0.030 0.401
Fibrinogen baseline 0.002 0.232
Factor VIII activity baseline 0.005 0.615
Protein C activity baseline 0.004 0.868
Protein S activity baseline 0.004 0.831
von Willebrand factor activity baseline 0.004 0.763
Antithrombin III activity baseline 0.008 0.261
*Two-way ANOVA for categorical factors, ANCOVA for metric covariables.
doi:10.1371/journal.pone.0112731.t005
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into the bile by the multidrug-resistance-protein-2. For Gd-EOB-
DTPA, the biliary excretion rate is approximately 50% in humans
[36,37]. Regardless of the mechanism of damage to liver, the
hepatobiliary contrast media in functionally altered liver paren-
chyma is significantly reduced [38]. This is also true for fRILI
since a loss of uptake of hepatobiliary contrast media is clearly
evident in the liver parenchyma adjacent to the clinical target
volume after local radiotherapy (Figure 2) [6,7]. Importantly, an
agreement has been found between the histopathological evidence
of fRILI/VOD and loss of hepatocellular uptake of hepatobiliary
contrast agent [24].
Unlike the reduced uptake of hepatobiliary contrast agents in
sinusoidal-obstruction-syndrome observed after platinum-contain-
ing chemotherapy (which is reticular in geometry and generalized
all over the liver) [39], the reduced uptake of hepatobiliary
contrast media after BT is focal, homogenous and circumferential
around the clinical target volume (Figure 1) [6,7]. Thus, we
believe that we can exclude underlying sinusoidal-obstruction-
syndrome as a confounder of our results. Additionally, the history
of platinum-containing chemotherapy was equal between the
groups and without influence on the endpoint.
We suggest that our study results can be transferred to other
established radiation treatment methods of liver malignancies such
as 90Y-radioembolization. According to conversion calculations,
the dose ranges in the liver parenchyma associated with 90Y-
radioembolization and BT are comparable, if re-calculated with
respect to the standard fractionation. We therefore hypothesize
that preventive treatment approaches against RILD/REILD
should be equally effective for both 90Y-radioembolization and
BT.
Conclusions
In summary, our results show a highly significant reduction in
fRILI after BT of colorectal liver metastases in patients who
received low-dose LMWH, PTX and UDCA. Further on, we
believe that these findings can be adopted for the prevention of
radiation-induced liver damage after other radiotherapeutic
approaches as 90Y-radioembolization and that further clinical
studies in this area are warranted.
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